Carl Zeiss Meditec 将来の成長

Future 基準チェック /36

Carl Zeiss Meditec利益と収益がそれぞれ年間16.3%と8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11.9% 16.9%なると予測されています。

主要情報

16.3%

収益成長率

16.9%

EPS成長率

Medical Equipment 収益成長	19.0%
収益成長率	8.0%
将来の株主資本利益率	11.9%
アナリストカバレッジ	Good
最終更新日	25 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

WBAG:AFX - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2027	2,691	316	238	N/A	6
9/30/2026	2,458	256	248	N/A	13
9/30/2025	2,277	204	209	N/A	15
9/30/2024	2,072	162	176	N/A	15
6/30/2024	2,066	203	N/A	N/A	N/A
3/31/2024	2,062	261	122	263	N/A
12/31/2023	2,094	277	N/A	N/A	N/A
9/30/2023	2,089	290	137	251	N/A
6/30/2023	2,080	308	N/A	N/A	N/A
3/31/2023	2,022	278	63	162	N/A
12/31/2022	1,963	307	N/A	N/A	N/A
9/30/2022	1,903	294	106	188	N/A
6/30/2022	1,781	245	N/A	N/A	N/A
3/31/2022	1,735	264	207	285	N/A
12/31/2021	1,688	228	N/A	N/A	N/A
9/30/2021	1,647	236	297	363	N/A
6/30/2021	1,566	235	N/A	N/A	N/A
3/31/2021	1,388	159	240	290	N/A
12/31/2020	1,335	130	N/A	N/A	N/A
9/30/2020	1,335	122	134	179	N/A
6/30/2020	1,400	120	N/A	N/A	N/A
3/31/2020	1,507	166	132	171	N/A
12/31/2019	1,505	170	N/A	N/A	N/A
9/30/2019	1,459	160	173	220	N/A
6/30/2019	1,382	153	N/A	N/A	N/A
3/31/2019	1,334	129	195	242	N/A
12/31/2018	1,310	127	N/A	N/A	N/A
9/30/2018	1,281	126	152	187	N/A
6/30/2018	1,251	124	N/A	N/A	N/A
3/31/2018	1,216	129	N/A	56	N/A
12/31/2017	1,205	132	N/A	N/A	N/A
9/30/2017	1,190	134	N/A	38	N/A
6/30/2017	1,154	123	N/A	N/A	N/A
3/31/2017	1,135	112	N/A	85	N/A
12/31/2016	1,106	113	N/A	N/A	N/A
9/30/2016	1,088	98	N/A	112	N/A
6/30/2016	1,090	78	N/A	132	N/A
3/31/2016	1,083	80	N/A	96	N/A
12/31/2015	1,062	61	N/A	73	N/A
9/30/2015	1,040	62	N/A	57	N/A
6/30/2015	984	70	N/A	34	N/A
3/31/2015	946	66	N/A	44	N/A
12/31/2014	938	73	N/A	60	N/A
9/30/2014	909	75	N/A	63	N/A
6/30/2014	931	83	N/A	74	N/A
3/31/2014	924	89	N/A	69	N/A
12/31/2013	900	89	N/A	52	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AFXの予測収益成長率 (年間16.3% ) は貯蓄率 ( 1.4% ) を上回っています。

収益対市場: AFXの収益 ( 16.3% ) はAustrian市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高成長収益: AFXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AFXの収益 ( 8% ) Austrian市場 ( 0.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: AFXの収益 ( 8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AFXの自己資本利益率は、3年後には低くなると予測されています ( 11.9 %)。

Carl Zeiss Meditec 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Carl Zeiss Meditec AG Reaffirms Earning Guidance for 2022

Carl Zeiss Meditec AG Reaffirms Earnings Guidance for the Year 2021/22

Carl Zeiss Meditec AG Provides Earnings Guidance for the Year 2021

Carl Zeiss Meditec AG Provides Earnings Guidance for the Year 2021

Recent updates

Now 18% overvalued

Investor sentiment improves as stock rises 17%

New minor risk - Profit margin trend

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Carl Zeiss Meditec AG to Report Nine Months, 2024 Results on Aug 06, 2024

ZEISS Announces OCT Technology Enhancements to Better Support Growing Era of Data-Driven Patient Care

Second quarter 2024 earnings released: EPS: €0.52 (vs €0.69 in 2Q 2023)

Carl Zeiss Meditec AG (XTRA:AFX) completed the acquisition of Dutch Ophthalmic Research Center (International) B.V. from Eurazeo China Acceleration Fund and Eurazeo Capital IV funds managed by Eurazeo SE (ENXTPA:RF).

Carl Zeiss Meditec AG (XTRA:AFX) completed the acquisition of Dutch Ophthalmic Research Center (International) B.V. from Eurazeo China Acceleration Fund and Eurazeo Capital IV funds managed by Eurazeo SE (ENXTPA:RF).

Upcoming dividend of €1.10 per share

First quarter 2024 earnings released: EPS: €0.42 (vs €0.57 in 1Q 2023)

Carl Zeiss Meditec AG to Report First Half, 2024 Results on May 08, 2024

Carl Zeiss Meditec AG, Annual General Meeting, Mar 21, 2024

Carl Zeiss Meditec AG Announces U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Full year 2023 earnings released: EPS: €3.25 (vs €3.29 in FY 2022)

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

New minor risk - Share price stability

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

ZEISS Reimagined the Iconic Pentero Platform for Digital Age

Third quarter 2023 earnings released: EPS: €1.03 (vs €0.70 in 3Q 2022)

New minor risk - Share price stability

Upcoming dividend of €1.10 per share at 0.8% yield

First quarter 2023 earnings released: EPS: €0.57 (vs €0.42 in 1Q 2022)

Full year 2022 earnings released: EPS: €3.29 (vs €2.64 in FY 2021)

Carl Zeiss Meditec AG to Report Q1, 2023 Results on Feb 10, 2023

Carl Zeiss Meditec AG Reaffirms Earning Guidance for 2022

Carl Zeiss Meditec AG (XTRA:AFX) acquired Kogent Surgical, LLC and Katalyst Surgical, LLC.

Upcoming dividend of €0.90 per share

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Carl Zeiss Meditec AG Reaffirms Earnings Guidance for the Year 2021/22

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Upcoming dividend of €0.50 per share

Second quarter 2021 earnings released: EPS €0.61 (vs €0.28 in 2Q 2020)

Carl Zeiss Meditec AG Provides Earnings Guidance for the Year 2021

Carl Zeiss Meditec AG Provides Earnings Guidance for the Year 2021

First quarter 2021 earnings released: EPS €0.52 (vs €0.43 in 1Q 2020)

Revenue beats expectations

New 90-day high: €137

Carl Zeiss Meditec AG, Annual General Meeting, May 27, 2021

Carl Zeiss Meditec AG to Report Nine Months, 2021 Results on Aug 06, 2021

New 90-day high: €123

ZEISS Presents its New Solution Enhancements to Help Doctors Maximize Clinical Efficiency and Improve Patient Care - from Assessment, Diagnosis, to Treatment

New 90-day high: €101

New 90-day high - €95.35

New 90-day high - €94.60

Upcoming Dividend of €0.65 Per Share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘